ClinicalTrials.gg
RecruitingNCT07655479RISEUpdated Nov 18, 2026

Rapid Impella Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support

An observational study in Cardiogenic Shock Post Myocardial Infarction, sponsored by University Hospital of Cologne. Recruiting at 3 sites in Germany. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University Hospital of Cologne · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 18, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
115
Ages
18 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.

Planned enrollment
9th of 14
115 · median 138
Started
2026
with 1 other
Observational
14 of 36
8 open now
Primary completion
2028-10
later than 6 of 12 live
Registered
35th of 36
by date

Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 9th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2026, is one of 14 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 35th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Shock, Cardiogenic with a site in Germany, or all of them as a file.
02

Study summary

The aim of this trial is to evaluate whether a structured and time-optimized escalation strategy from a transfemoral microaxial flow-pump (Impella CP™) to the Impella 5.5™ microaxial flow-pump is associated with improved clinical outcomes and fewer adverse events in patients with cardiogenic shock due to acute myocardial infarction

Read the detailed description

By examining best-practice MCS management and the role of early escalation to Impella 5.5™ in clinical routine care for high-risk patients with deteriorating shock, the study seeks to investigate current treatment strategies that ensure the most appropriate device selection and support intensity at the earliest clinically meaningful time point. This observational approach aims to advance the optimal management of ACS-CS while addressing the complications reported in the DanGer Shock trial.

03

Conditions studied

  • Cardiogenic Shock Post Myocardial Infarction

Keywords

  • Impella
  • Microaxial Flow-pump
  • cardiogenic shock
  • myocardial infarction
04

Who can participate

Ages eligible
18 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with ACS-CS (STEMI or NSTEMI) who undergo Impella CP™-supported revascularisation of the culprit lesion and are considered for escalation to Impella 5.5 at the discretion of the treating investigator will be assessed for eligibility to participate in this observational study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤77 years
  2. Patients with ACS-CS (STEMI and NSTEMI with a culprit lesion that received revascularisation) and Impella CP™ support during initial revascularisation
  3. The following additional parameters must be met at the time of initial revascularisation procedure:

    1. Hypotension or need for inotropes AND
    2. Lactate > 2.5 mM AND
    3. (EF) \< 45%
  4. Need for escalation to Impella 5.5 at the discretion of the treating physician and the following criteria are fulfilled:

    1. Decision for Impella 5.5 escalation within 6 ± 1 hours after completion of initial revascularisation procedure
    2. Escalation to Impella 5.5procedure is initiated within 24 hours after completion of the initial revascularisation procedure
  5. Need for inotropes and/or vasopressors with VIS > 5 but ≤ 50 at Impella CP™ support at level P7 or above at 6+1 hours after completion of initial revascularisation procedure
  6. Prospective obtained from the patient or deferred consent according to "Cologne Model" applied.

Exclusion criteria

Exclusion Criteria:

  1. Implanted VA-ECMOwithin 6 ± 1 hours after initial revascularisation Note: If VA-ECMO support is needed between 6 ± 1 hours after initial revascularisation and escalation to Impella 5.5, patients will be included forlimited data collection per Table 2 only. In this case the same Process as for regular trial participants applies.
  2. Elevated risk of hypoxic brain injury indicated by MIRACLE2 score >3 (Aldous et al., 2023)
  3. count \<75,000 cells/mm3, bleeding diathesis or active bleeding, coagulopathy or unwillingness to receive blood transfusions
  4. Active bleeding (e.g. access site bleeding or GI bleeding, etc.) with need for transfusion within 6 ± 1 hours after initial revascularisation
  5. Any listed in the Impella 5.5 IFU if known to be present
  6. Chronic haemodialysis and/or chronic kidney disease stage G5 according to KDIGO
  7. Pregnancy or lactation, if known
  8. Participation in the active treatment or follow-up phase of another clinical study of an drug or device that has not reached its primary endpoint, if known
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
115 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Device Group

    Rapid escalation to Impella 5.5

    Device: Escalation to more capable microaxial flow-pump (Impella 5.5)

Interventions

  • DeviceEscalation to more capable microaxial flow-pump (Impella 5.5)

    Rapid escalation from Impella CP to Impella 5.5 within 24 hours post revascularization

06

What researchers measure

Primary outcomes

  1. Vasoactive Hemodynamic Score (VHS) < 5

    Vasoactive Hemodynamic Score = Hemodynamic Score (HS) x Vasoactive-Inotropic Score (VIS) Higher VHS indicates more severe hemodynamic compromise relative to degree of pharmacological circulatory support. Range: Minimum 1, Maximum 110 Hemodynamic Score: HS = Points are allocated for measured heart rate, mean arterial blood pressure and arterial lactate (minimum 1, maximum 11) Vasoactive-Inotropic Score: Points are allocated for every 10 increment according to the following formula: Dopamine dose (μg/kg/min) + Dobutamine dose (μg/kg/min) + 100 x Epinephrine dose (μg/kg/min) + 10 x Milrinone (μg/kg/min) + 100 x Norepinephrine dose (μg/kg/min) + 50 x Levosimendan dose (μg/kg/min)

    Time frame: 48 hours post revascularization

Secondary outcomes

  1. All-cause mortality

    Time frame: In-hospital or 30 days post revascularization (whatever comes first)

  2. All-cause mortality

    Time frame: 180 days post revascularization

  3. Cardiac output

    measured by pulmonary artery catheter (PAC) \[l/min\]

    Time frame: At time of enrolment, 48 hours as well as 72 hours post revascularization.

  4. Vasoactive-Inotropic Score (VIS)

    Vasoactive-Inotropic Score (VIS): A composite measure of vasoactive and inotropic medication support. Scores range from 0 to no fixed maximum, with higher scores indicating greater vasoactive/inotropic support requirements and therefore a worse clinical status and prognosis. VIS=dopamine + dobutamine + 100×epinephrine + 10×milrinone + 10,000×vasopressin + 100×norepinephrine (all doses in μg/kg/min except vasopressin in U/kg/min)

    Time frame: At time of enrolment, 48 hours as well as 72 hours post revascularization.

  5. Lactate

    Arterial lactate measured by blood gas analysis \[mmol/l\]

    Time frame: At time of enrolment, 48 hours as well as 72 hours post revascularisation

  6. Perfusion

    Enhanced perfusion of the limb used for Impella CP™ access by comparing NIRS measurements \[%\]

    Time frame: At time of enrolment and 48 hours post revascularization.

  7. Major Bleeding

    Either according to BARC classification (BARC ≥ IIIa) or GUSTO classification (at least moderate bleeding)

    Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) until the first documented bleeding event.

  8. Ischemia of the extremities

    Peripheral vascular ischemia (femoral and axillary) with indication to percutaneous intervention or surgical repair

    Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) at the timepoint of intervention/surgery assessed up to 30 days.

  9. Haemolysis

    Prevalence of clinically relevant haemolysis according to SHARC definitions

    Time frame: At time of enrolment, 48 hours as well as 72 hours post revascularization.

  10. Cerebral events

    Cerebral ischemia or cerebral bleeding assessed via standard-of-care neurological assessment and/or imaging

    Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) assessed up to 30 days.

  11. Acute kidney injury (AKI)

    Acute kidney injury (AKIN level 2 or greater) and/or need for renal replacement therapy (RRT)

    Time frame: Every event during the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first), assessed at the timepoint of occurence up to 30 days.

  12. Sepsis with positive blood culture

    Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) at the timpoint of first positive blood culture up to 30 days.

  13. Access site infection

    Access site infection with the need to surgical intervention

    Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death (whichever comes first), at the timepoint of surgical intervention up to 30 days.

  14. Time to extubation

    Time to extubation in hours

    Time frame: At 30 days post revascularization

  15. Time to ambulation

    Time to ambulation in hours

    Time frame: At 30 days post revascularization

  16. Cumulative incidence of escalation to VA-ECMO, LVAD or heart transplant

    Cumulative incidence of escalation to VA-ECMO, LVAD or heart transplant

    Time frame: At 30 days and 180 days post revascularization

  17. Major adverse kidney events (MAKE)

    Death (from any cause) or new requirement for renal replacement therapy (RRT) (e.g., dialysis) or persistent renal dysfunction (PRD) (defined as a worsening of kidney function denoted by ≥ 25% decline in the estimated glomerular filtration rate (eGFR) from baseline)

    Time frame: At 30 days and 180 days post revascularization

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to data protection regulations and study contracts

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2028, 30 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 30 months is below that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Jun 17, 2026
StartActual
Apr 23, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Rapid Microaxial Flow PumpImpella Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Title Rapid Microaxial Flow PumpImpella Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07655479
Lead sponsor
University Hospital of Cologne
Collaborators
Johnson & Johnson
Responsible party
Stephan Baldus (Prof. Dr. med., University Hospital of Cologne) — Principal investigator
First posted
Jun 17, 2026
Start date
Apr 23, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Sebastian Heyne, Dr. med.
Contact
sebastian.heyne@uk-koeln.de
+4915125364083

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion